Latest Brain tumor Stories
Funding Includes $25 Million Equity Investment By Leading UK Investment Fund and $10 Million Mortgage Financing BETHESDA, Md., Nov.
Results Presented at the 19th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology MIAMI, Nov.
Data Presented at the 19th Annual Society for Neuro-Oncology Meeting Demonstrate VAL-083 Superiority to Temozolomide in Key Preclinical Models VANCOUVER, British Columbia, MENLO PARK, Calif.,
Data presented today as a late-breaking abstract at the Society for Neuro-Oncology 2014 Annual Meeting in Miami demonstrated the EF-14 trial met its primary endpoint of progression-free survival and
- Data include results from a Phase 1 study of ABT-414 as monotherapy and in combination with radiation and/or chemotherapy in patients with newly diagnosed and recurrent/unresectable glioblastoma
VAL-083 Anti-tumor Activity Is Consistently Superior to Temozolomide in Preclinical Models of Glioblastoma VANCOUVER, British Columbia, MENLO PARK, Calif., and MIAMI, Nov.
Builds Expert Independent Board As Company Advances Towards Late-Stage Brain Cancer Trials SAN DIEGO, Nov.
Continued Positive Trends in Overall Survival and Progression-Free Survival; LOS ANGELES, Nov. 14, 2014 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd.
- A small wooded valley; a dell.
- The protecting weather-shed built around the entrance to a house.
- The roofed-over space between the kitchen and the sleeping-quarters in a logging-camp, commonly used as a storeroom.